The weight loss drug boom isn't over yet — here's what to expect in the year ahead
2024 will be another big year for weight loss drugs, which soared in popularity despite hefty price tags, mixed insurance coverage and unpleasant side effects.
Patients Regain Weight After They Quit Using Ozempic Rival Zepbound. Here's Why That Makes Eli Lilly Stock an Even Better Buy.
A recent study found that patients who quit taking Lilly's Zepbound regain much of their weight. Investors viewed this as bad news for Lilly, but it's actually good news.
What Are The Best Stocks To Invest In Now? 2 Health Care Stocks To Watch
Health care stocks to check out in the stock market now.
Billionaire investor Ken Langone: Lilly will be the first trillion dollar drug company in history
Ken Langone, Invemed Associates chairman and Home Depot co-founder, joins 'Squawk Box' to discuss the state of the pharmaceutical industry, including Pfizer's weaker than expected 2024 forecast, th...
Eli Lilly Stock Slips After Reported Weight Gain In Users Who Quit Its Drug
Eli Lilly (LLY) shares fell 2.3% Monday after a study conducted by the drug maker found patients who use its weight-loss treatments may gain weight once they stop taking the drugs.
Patients regain weight after stopping Eli Lilly's Zepbound, study says
The data suggests that people have to stay on the weekly injection Zepbound if they want to maintain weight loss.
Eli Lilly Stock Falls on Data That Show Patients Who Stopped Zepbound Regained Weight
A JAMA study shows that patients who stopped taking Zepbound after 36 weeks on the drug experienced a 14% weight regain over a year.
Here's what will happen if you stopped taking Eli Lilly's weight-loss drug
Eli Lilly & Co (NYSE: LLY) is down nearly 4.0% today after a study indicated that weight-loss from Zepbound tends to reverse once the treatment is stopped. Patients regain weight if they stop takin...
Eli Lilly obesity drug patients regained weight after ending treatment: study
Individuals using Eli Lilly and Co (NYSE:LLY)'s obesity drug Zepbound (tirzepatide) regained weight after they stopped using the treatment, according to a study published Monday in the Journal of t...
Patients on Eli Lilly's drug regain weight after stopping treatment - JAMA study
Patients on Eli Lilly's weight-loss drug trial substantially regained weight after stopping treatment, according to a study published in journal JAMA on Monday.
Eli Lilly (LLY) Rises Higher Than Market: Key Facts
The latest trading day saw Eli Lilly (LLY) settling at $598.05, representing a +1.66% change from its previous close.
Novo, Lilly rivals explore booming weight-loss drug market entry
Novo Nordisk and Eli Lilly have pulled ahead in the race for a slice of the weight-loss drugs market, expected to be worth $100 billion by the end of the decade, and rivals are looking to catch up ...
Could Eli Lilly Beat Novo Nordisk in the Billion-Dollar Weight Loss Market?
Novo Nordisk was first to market with its blockbuster weight loss treatment Wegovy. Doctors have prescribed Eli Lilly's diabetes treatment for weight loss.
Better Large-Cap Growth Fund: Schwab U.S. Large-Cap Growth or Vanguard Growth Index Fund?
Large-cap growth stocks have been major drivers of total stock market returns over the past century. This fact has driven a sharp rise in the popularity of large-cap growth ETFs over the past two d...
Eli Lilly weight loss drug Zepbound now available at pharmacies as rival Wegovy faces shortages
Eli Lilly's drug serves as an alternative to rival obesity drugs such as Wegovy that are still facing supply issues.
Related Companies